Abstract
We thank Drs Uzun, Sinha, and Beattie for taking interest in our study. We fully agree that sustained fetal supraventricular tachycardia and atrial flutter (AF) is a life-threatening situation, and maternal drug therapy is therefore offered in the majority of these cases. In 1980, the first report appeared of a hydropic fetus with incessant supraventricular tachycardia that was successfully treated with transplacental digoxin therapy.1 Since then numerous retrospective studies in fetal supraventricular arrhythmia (SVA) have looked at different maternal drug therapies showing variable results.2 Our study indicates that digoxin and flecainide controls fetal SVA more effectively than sotalol, although we were unable to find differences in survival among the 3 drug cohorts. Despite relatively low conversion rates, …
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call